Tradestie Institutional Equity Comparison Engine

WVE vs VOR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VOR Overall Edge

VOR Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vor Biopharma Inc. Common Stock (VOR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, WVE trades at N/M Forward P/E with -320.9% operating margin (+73.0% YoY revenue) versus VOR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, WVE sits in BREAKDOWN (62nd %ile IV; Dealer Gamma Walls on Pro) against VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VOR
WVE N/M vs VOR N/M Fwd P/E
Growth & Margin Winner VOR
Op Margin -320.9% vs 0.0% ยท YoY +73.0% vs +0.0%
Momentum & Technical Winner VOR
1Y -56.8% vs +97.5% ยท 52W Pos 0% vs 65%
Options & Structure Winner VOR
BREAKDOWN (62nd %ile IV) vs CONSOLIDATION (6th %ile IV)
WVE NASDAQ
Wave Life Sciences Ltd. Ordinary Shares
Pharmaceutical Preparations
$2.89
-7.82% 1D
Market Cap $621.3M
1M Return -7.82%
1Y Return -56.75%
Forward P/E N/M
Unified AI Score
41.5 / 100 SELL
Tech 21.0 Fund 46.0 Flow 68.0 Mom 60.0
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
1M Return +6.82%
1Y Return +97.54%
Forward P/E N/M
Unified AI Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: WVE -56.75% VOR +97.54% Spread: +154.29 pp (VOR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
WVE TTM Op. Margin: -320.9% VOR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WVE vs VOR. Trailing 12-month operating profitability (WVE -320.9% vs VOR 0.0%) and valuation multiples (WVE N/M vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: WVE (2) vs VOR (7)
Institutional Metric WVE VOR Criterion Row Winner
Market Capitalization Scale $621.3M $1.2B Larger Scale VOR
Trailing P/E Ratio Valuation N/M 0.1x Lower Multiple VOR
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +73.0% +0.0% Higher Growth WVE
Operating Margin (TTM) Profitability -320.9% 0.0% Higher Margin VOR
Net Profit Margin Profitability -296.9% 0.0% Higher Margin VOR
Return on Equity (ROE) Capital Efficiency -78.8% -125.4% Higher ROE WVE
52-Week Range Position Momentum 0% ($3โ€“$21) 65% ($6โ€“$26) Stronger Trend VOR
Beta / 30D Volatility Risk Regime 1.94ฮฒ ยท 76% Vol 1.91ฮฒ ยท 61% Vol Lower Realized Risk VOR
Unified Institutional Score Composite Signal 41.5 / 100 (SELL) 57.8 / 100 (HOLD) Higher Composite VOR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full WVE vs VOR Buy Guide
WVE BREAKDOWN
149d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 62nd %ile
IV Regime Elevated (60thโ€“80th %ile)
Live WVE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither WVE nor VOR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.